2024年10月1日 · Survival outcomes of grade group 5 (GG5) prostate cancer (PCa) after standard of care therapy (SOC) remain poor. Evidence suggests that high-dose rate brachytherapy (HDR) and androgen deprivation therapy (ADT) can serve as immune modulators.

1 天前 · Notably, GG5, representing the most aggressive form of PCa, exhibited the highest prevalence of PD-L1 expression. This finding carries substantial clinical implications, particularly in the context of immunotherapy, suggesting that GG5 PCa patients, who are more likely to express PD-L1, might be particularly suitable candidates for ICI therapy.

2020年7月10日 · To determine whether combining brachytherapy with immunotherapy is safe in prostate cancer (PCa) and provides synergistic effects, we performed a Phase I/II trial on the feasibility, safety, and...

Aims: Grade Group 5 (GG5) prostate cancer (PCa) is associated with a high risk of disease recurrence after radical prostatectomy (~75% at 5 years). However, this is a heterogeneous category that includes neoplasms with different combinations of Gleason pattern (GP) 4 and 5.

2020年3月15日 · The five-tier grade group (GG) classification for prostate cancer (PCa) does not differentiate between primary (5+4) or secondary (4+5) histological Gleason 5 pattern in GG 5. We addressed the prognostic value of primary versus secondary biopsy Gleason 5 for GG 5 among 18 555 PCa patients treated wi …

2017年10月3日 · We assessed Gleason pattern 5 (GP5) and other prostatic adenocarcinoma (PCa) morphologies to determine their association with biochemical recurrence (BCR). A search for grade group 5 PCa with radical prostatectomy (RP) yielded 49 patients.

2022年5月5日 · After the definition of the GG system, more relevance has been given to the difference between GS 8 (GG 4) and GS 9–10 (GG5) PCa. Recent studies demonstrated that GS 9–10/GG 5 hormone sensitive PCa may benefit less from androgen deprivation therapy (ADT) and should be treated with lifelong ADT, on the contrary, GS 8 or GG4 PCa may benefit ...

2023年4月14日 · Here we report an interim analysis of a single-center single-arm phase II trial exploring this novel combination therapy with nivolumab for GG5 PCa. Patients were enrolled from 9/2018 to 4/2021 and required to have GG5 PCa with > 30% positive cores and receive ICI plus SOC regimen, comprising ADT, external beam RT (EBRT), and HDR.

The most significant predictor of pN+ PCa was ISUP GG4 (odds ratio [OR] 12.5, P< .001) and GG 5 (OR 26.2, P < .001). Rates of pN+ identification increased from 5.5% to 9.4% in men with GG4 and from 13.4% to 19.5% in men with GG5 (P< .001). In GG4 and GG5, patients undergoing PLND had superior survival to those managed without PLND (P < .01).

2020年4月1日 · In men undergoing treatment for clinically localized disease, pathogenic mutations in 13 commonly assayed genes, especially ATM, BRCA2, and MSH2, are most strongly associated with GG5 PCa. These findings emphasize the importance of genetic testing in men with high-grade PCa, particularly GG5 disease, to inform both treatment decisions and ...